Due to the Pre-Clinical Data and Initial Clinical Data from Cardiol’s Maverick-Pilot Phase II Study of Pericarditis, it has been granted Orphan Drug Designation for its lead drug candidate for the treatment of Pericarditis.
Cardiol Therapeutics is also involved in another trial for Acute Myocarditis, the Archer Trial, for which they are recruiting patients.
Read about them below:
